Bregal Milestone Announces Strategic Growth Investment in Ridango
Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in Ridango, a global provider of mission-critical public transportation software. The investment is made in partnership with founder Erki Lipre and the Ridango management team. Terms of the transaction were not disclosed.
Founded in 2009, Ridango is a global market leader in intelligent transportation software for public transport authorities, municipalities, cities, and private transport operators. Ridango has built one of the world’s leading integrated automated fare collection and operations control software platforms, serving more than 150 customers in over 25 countries across five continents. The Company’s modern software provides end-to-end transit management services, from account-based ticketing to contactless bank card acceptance, real-time passenger information, and automatic vehicle location operations management to deliver better transit services, more accurate real-time visibility, and improved passenger satisfaction.
With operational and financial support from Bregal Milestone, Ridango aims to accelerate its organic and inorganic growth. Following accelerated customer activity in Sweden, including customer wins from Västtrafik, Sörmlandstrafiken, and Västmanlandstrafiken, the Company will operate from its new European headquarters in Sweden; its R&D hubs in Estonia and Slovenia; and its regional sales and marketing hubs following major customer wins in the Middle East (UAE, Qatar, and Saudi Arabia) and APAC (Singapore and Hong Kong).
“Our partnership with Bregal Milestone marks a significant next step in our growth strategy. We extend our sincerest thanks to our prior investors, BaltCap Private Equity, and look forward to the proactive support and expertise from Bregal Milestone and their in-house value creation team, Milestone Performance Partners, to help accelerate our investment in next-generation technology and accelerate our GTM activity in new markets,” said Erki Lipre, Founder and CEO of Ridango. "Public transportation is at the heart of sustainable urban development, and the team at Ridango is tirelessly committed to delivering the most advanced solutions to help modernize transit networks for the future."
“Ridango’s strong commitment to innovation has positioned it as a software operating system of choice for transit operators looking to modernize fare collection and optimize passenger experience,” added Cyrus Shey, Managing Partner at Bregal Milestone. “We see strong secular tailwinds as private transport operators and public rail and mass transport operators accelerate investments in digitalization, underpinned by the accelerated shift from card-based ticketing to account-based ticketing systems, and we are thrilled to partner with Erki and his leadership team to support Ridango in capitalizing on these megatrends.”
Sebastian Charpentier, Principal at Bregal Milestone, adds, “We are honored to enter this strategic partnership with Ridango, a company that continues to drive innovation and deliver customer service with what we see as the most advanced end-to-end transit software offerings featuring AI-driven predictive analytics and cloud-based fare collection. We believe that Ridango is uniquely positioned to lead the digital transformation for public transportation authorities and operators alike, creating sustainable long-term value for the communities in which they operate.”
White & Case served as legal counsel and Deloitte as financial advisor for Bregal Milestone. Sorainen served as legal counsel for Ridango.
The transaction will be closed after necessary regulatory approvals have been obtained.
About Bregal Milestone
Bregal Milestone is a leading software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €19 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2024. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Ridango
Ridango is the software operating system of choice for public transportation providers globally, specializing in automated fare collection (“AFC”), real-time passenger information systems, automatic vehicle location tracking (“AVL”), and mobility-as-a-service (“MaaS”) technology. The company partners with transport authorities and operators to enhance the efficiency, accessibility, and sustainability of public transit for customers and operators alike.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319073578/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Network APIs Pave the Way for Freenow by Lyft to Advance Urban Mobility Innovation22.1.2026 08:00:00 CET | Press release
Freenow adopts Vonage APIs to access network capabilities, strengthening fraud prevention through faster, verified connections with drivers for millions of riders Vonage, a part of Ericsson, and Freenow by Lyft, a leading taxi and multi-mobility app in Europe, have expanded their partnership with the launch of Vonage Silent Authentication API for customers based in the U.S. Vonage Network APIs enable Freenow by Lyft to tap into real-time network data and insights, helping prevent fraud through seamless user verification, ensuring reliable, efficient, and secure interactions for its customers and drivers. Network intelligence is becoming a critical layer of defense in the transportation space as fraud threats become more sophisticated and targeted. Enterprises worldwide lost 7.7% of their annual revenue on average due to fraud over the past year, representing an estimated $534 billion in losses.¹ With scam/authorization fraud, synthetic identity fraud, and account takeover as the leadin
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe22.1.2026 07:30:00 CET | Press release
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell Research Center Munich, has grown from three to 40 researchers since it was founded in 1997 and has become an internationally recognized institution that plays a strategic role in the global innovation process of Daiichi Sankyo. Dr. Veronika Rozehnal joined Daiichi Sankyo in 2009 and has held various positions at the Translational Research Center Europe in addition to spending three years at the Daiichi Sankyo R&D Center in Tokyo. Dr. Rozehnal graduated from Ernst-Moritz-Arndt University of Greifswald, Germany with a Ph.D. degree in Clinical Pharmacology. “Jürgen Müller has made significant scientific contributions that have helped Daiichi Sankyo
Azafaros Announces Key Scientific Oral and Poster Presentations on Nizubaglustat Accepted for WORLDSymposium™ 202622.1.2026 07:00:00 CET | Press release
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C disease and GM1/GM2 gangliosidoses which are currently recruiting. Azafaros will host a satellite symposium on nizubaglustat on Day 2 of the symposium discussing the Phase 3 studies. WORLDSymposium™ 2026 takes place from February 2 to 6 in San Diego, California. Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (including Poster numbers 134 and 29-C) Long-term data from a Phase II study wit
I Squared Announces Launch of Radiant Energy Solutions22.1.2026 07:00:00 CET | Press release
I Squared Capital (“I Squared”), a leading global infrastructure investment manager, announced today the launch of Radiant Energy Solutions (“Radiant”), an investment from I Squared’s Middle East infrastructure strategy, which is focused on targeting transformational, mid-market investments in the region. Reflecting I Squared’s platform-building approach of starting with a core initial investment and scaling over time to build market-leading businesses, Radiant marks the firm’s entry into the Middle East distributed renewables market, providing decarbonization solutions to commercial and industrial customers. The investment for Radiant is the acquisition of FAS Renewables and its 100% owned subsidiary Zahra Energy, a Saudi Arabia–based distributed solar company with a secured and advanced portfolio of over 100MWp of distributed solar projects with established customers and long-term contracted solar power purchase agreements. These include Cenomi Centers, an owner, operator, and develo
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio22.1.2026 07:00:00 CET | Press release
At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane® Shaype™ in shaping the chin, Restylane Lyft™ in improving jawline definition, Restylane Skinboosters™ in smoothing fine lines and wrinkles in the décolletage and Restylane Volyme™ in correcting hollowing of the temples8-11 New data on the innovative neuromodulator Relfydess™ (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow’s feet12 As a leader in injectable aesthetic innovation, Galderma will showcase its superior science and edu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom